Table 1. miRNome analyses in cancers.
Tumor type | Profiling method |
miRNAs deregulated in tumor | note | ref | |
---|---|---|---|---|---|
up-regulated | down-regulated | ||||
breast cancer | bead | classification of breast tumors into five sub-types |
(93) | ||
breast tumor | qRT-PCR array |
miR-21 | (165) | ||
breast cancer | array | classification according to ErbB2/ER status |
(158) | ||
breast cancer | array | miR-21 | miR-125b, -145 | clinicopathologic features | (185) |
prostate cancer | array |
let-7c, miR- 125b, miR-145 |
(186) | ||
prostate cancer | membrane | classification according to androgen dependency |
(66) | ||
prostate cancer | array | (158) | |||
pancreatic cancer |
array | miR-21, -221, -222, -181a, -181b, - 181d, -155 |
vs. chronic pancreatitis and normal tissues |
(187) | |
pancreatic cancer |
array | miR-196a | miR-217 | pancreatic ductal adenocarcinoma vs. chronic pancreatitis and normal tissues |
(160) |
pancreatic cancer |
qRT-PCR of pre- miRNA |
let-7i, miR-100, - 155, -221, -301, - 21,-181a, -125b, - 212, -376a |
miR-375 | pancreatic adenocarcinoma, paired benign tissue, normal pancreas, chronic pancreatitis |
(188) |
pancreatic tumor |
array | miR-103, -107, - 23a, -26b, -342, - 192, -204, -211, -21 |
miR-155 | endocrine tumors vs. acinar cell carcinoma |
(189) |
lung cancer | array | miR-21, -205 | miR-126* | clinicopathological features |
(190) |
ovarian cancer | array | miR-200a, -141 | miR-199a, -140, -145, -125b1 |
clinicopathological features |
(191) |
cervical cancer | array | vs. Drosha overexpression | (95) | ||
uterine leiomyoma |
array | let-7, miR-21, -23b | clinicopathological features (tumor size, race, etc) |
(192) | |
hepatocellular cancer |
array | miR-21 | (134) | ||
hepatocellular cancer |
array | miR-221 | let-7a, miR-122a | vs. liver cirrhosis | (193) |
hepatocellular cancer |
array | miR-224, -18 | miR-199a, - 199a*, -200a |
(194) | |
thyroid cancer | array | miR-30d, -125b, -26a, and -30a- 5p |
anaplastic thyroid carcinomas vs. normal tissues |
(67) | |
thyroid cancer | array | miR-197, -346 in FTC relative to FA |
follicular thyroid carcinoma (FTC) vs. follicular adenoma (FA) |
(195) | |
thyroid cancer | array | miR-221, -222, - 181b |
papillary thyroid carcinoma vs. normal tissues |
(159) | |
thyroid cancer | array | miR-221, -222, - 146b |
papillary thyroid carcinoma vs. normal tissues |
(100) | |
colorectal cancer |
array | miR-25, -92 in MSS relative to MSI-H |
microsatellite stability (MSS) vs. high microsatellite instability (MSI-H) |
(196) | |
colorectal cancer |
qRT-PCR | miR-31, -96, -135b, -183 |
miR-133b, -145 | miR-31 according to cancer stage |
(197) |
colorectal cancer |
cloning miSAGE |
(17) | |||
pituitary adenomas |
array | miR-26a, -149 | miR-21, -141, - 144 |
clinicopathological features |
(198) |
neuroblastoma | qRT-PCR | neuroblastoma subtypes | (69) | ||
glioblastoma | array | miR-221. -10b | miR-128, -181b, -181a |
(199) | |
leukemia | bead | miR-128a, -128b in ALL compared with AML |
let-7b, miR-223 in ALL compared with AML |
acute lymphoblastic leukemia (ALL) vs. acute myeloid leukemia (AML) |
(200) |
leukemia | cloning | miR-21, -150, -155 | miR-92, -222 | various chronic lymphocytic leukemias (CLL) |
(201) |
leukemia | array | miR-29b, -181b in aggressive CLL with 11q deletion |
three subtypes of CLL | (202) | |
leukemia | array | miR-16-1,-15a | CLL according to ZAP-70 and IgVH |
(203) | |
leukemia | array | B-cell CLL | (65) | ||
various tumors | array cloning |
various sarcomas | (204) | ||
various tumors | array | solid tumors (lung, breast, stomach, prostate, colon, and pancreatic tumors) |
(122) | ||
various tumors | bead | comprehensive collection of various cancers and normal tissues |
(64) |